N/A N=164 Extracardiac Complications After Cardiac Surgery
Acute Lung Injury · Sepsis · Infections
Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,136 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Cardiovascular Diseases · Coronary Disease · Heart Failure, Congestive
Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12
Phase 4 N=314 Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Aortic Valve Disease · Mitral Valve Disease
Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354
Phase 3 N=201 Risk of Oxygen During Cardiac Surgery Trial
Cardiac Surgery
Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml
Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
Phase 4 N=57 Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients
Reperfusion Injury
Primary: Mortality — 0; 0 participants
Phase 1 N=6 Utilization of Confocal Microscopy During Cardiac Surgery
Atrial Septal Defect
Primary: Number of Participants Who Experienced Adverse Events Possibly Related to Study Intervention — 0; 6 Participants
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
Phase 2 N=51 Measures to Lower the Stress Response in Pediatric Cardiac Surgery
Tetralogy of Fallot (TOF) · Ventricular Septal Defects (VSD) · Atrioventricular Septal Defects (AVSD)
Primary: ACTH and Cytokine Levels — 116.9; 182.7; 135.3; 44.5 pg/mL
N/A N=180 GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery
Reduction of Length of Hospitality Stay, Reduction of Perioperative Complications
Primary: Postoperative Complications — 52; 72 numbers of complications
N/A N=60 Prophylactic Maze to Prevent Atrial Fibrillation in Adult Cardiac Surgery
Coronary Artery Disease
Primary: Incidence of Documented Post-operative Atrial Fibrillation — 17; 2 Participants
Early Phase 1 N=40 Telemedicine in Cardiac Surgery: A Pilot Study
Coronary Artery Disease
Primary: Accuracy (FTF Decision on Patient Disposition vs. V-visit Decision on Patient Disposition) — 89 percentage of agreement
N/A N=1,439 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery
Cardiac Surgery
Primary: Any Major Morbidity/30-day Mortality — 46; 82 Participants — p=0.0043
N/A N=89 Pre-operative Rehabilitation for Reduction of Hospitalization After Coronary Bypass and Valvular Surgery.
Patients Waiting for Coronary Artery Bypass Graft Surgery · Patients Waiting for Aortic Valve Repair or Replacement · Patients Waiting for Mitral Valve Repair or Replacement
Primary: Proportion of Patients With Hospital Length of Stay Greater Than 7 Days. — 20; 16 Participants
N/A N=34 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
Phase 4 N=91 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
N/A N=19 Robotic Cardiac Surgery Wet Lab Simulation Study
Robotic Cardiac Surgery Simulation
Primary: Time-based Score — 553; 127; 143 score on a scale
Phase 3 N=33 Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures
Atrial Fibrillation
Primary: Incidence of Postoperative Atrial Fibrillation — 5; 4; 5 participants
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
N/A N=40 Intraoperative Echocardiography in Low-Risk CABG Surgery
Heart Diseases · Coronary Artery Disease · Chest Pain
Primary: Enrollment and Randomization Feasibility — 40 Participants
Phase 2 N=22 Cardiac Surgery Neuroprotection Study in Elders
Post-operative Cognitive Decline · Post-operative Delirium
Primary: Change From Baseline Cognitive Function
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Phase 4 N=52 Regional Anesthesia Following Pediatric Cardiac Surgery
Atrial Septal Defect · Ventricular Septal Defect · Pain, Procedural
Primary: Total Amount of Opioid Medications Administered — 0.44; 0.83 MME/kg — p=0.001
Phase 2 N=11 AZD8601 Study in CABG Patients
Heart Failure
Primary: Number of Subjects With Adverse Events — 7; 4 Participants
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 3 N=304 Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
Atrial Fibrillation · Atrial Flutter
Primary: Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery — 50; 56; 58; 48 Participants
Phase 2 N=200 Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events